The U.S. Food and Drug Administration (FDA) has granted expedited approval to Rasonque (daraxonrasib), a groundbreaking RAS inhibitor for advanced pancreatic cancer. This marks a significant milestone: it’s the first-of-a-kind treatment targeting mutated proteins that drive tumor growth in more than 90% of pancreatic cancer cases. The approval was granted more than six months ahead of schedule, demonstrating the agency’s commitment to accelerating treatments for serious conditions. asahi.com +1
In a clinical trial involving 500 patients with metastatic pancreatic adenocarcinoma who had previously received systemic therapy, Rasonque demonstrated impressive results. Patients taking the drug nearly doubled their survival time compared to those receiving standard chemotherapy: median overall survival was 13.2 months versus 6.7 months. The FDA also granted the drug Breakthrough Therapy and Orphan Drug designations. asahi.com +1
However, like any treatment, it comes with potential side effects, including rash, diarrhea, stomatitis (inflammation of the mouth’s mucous membranes), nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.
About the Author
